EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

1,406

Participants

Timeline

Start Date

June 7, 2023

Primary Completion Date

July 1, 2031

Study Completion Date

July 1, 2031

Conditions
HER2 Positive Early Breast Cancer
Interventions
DRUG

Docetaxel

Docetaxel is a taxoid antineoplastic agent used in the treatment of breast cancer

DRUG

carboplatin

Carboplatin is a DNA synthesis inhibitor which binds to DNA, inhibits replication and transcription and induces cell death.

DRUG

Trastuzumab

Trastuzumab is a humanized monoclonal antibody derived from recombinant DNA,

DRUG

Pertuzumab

Pertuzumab is a recombinant humanized monoclonal antibody that specifically binds to the extracellular dimerization domain (subdomain Ⅱ) of epidermal growth factor receptor 2(HER2).

DRUG

Epirubicin

Epirubicin is an antineoplastic agent derived from doxorubicin.Epirubicin, like doxorubicin, exerts its antitumor effects by interference with the synthesis and function of DNA and is most active during the S phase of the cell cycle.

DRUG

cyclophosphamide

An anticancer (antitumor or cytotoxic) chemotherapy drug that is classified as an alkylating agent. Alkylating agents are compounds that prevent the normal connection of the double helix chain by adding an alkyl group to the guanine base of the DNA molecule. It causes breaks in DNA strands, affecting the ability of cancer cells to proliferate.

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT05883852 - EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer | Biotech Hunter | Biotech Hunter